Erlotinib-induced dermatologic side-effects.
Bovenschen
H Jorn
HJ
Alkemade
J A C Hans
JA
D017486:Acneiform Eruptions / Q000139:chemically induced*; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002644:Chickenpox / Q000175:diagnosis / Q000209:etiology*; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology*; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D014645:Herpesvirus 3, Human / Q000502:physiology*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*; D014775:Virus Activation / Q000187:drug effects*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D004815:Epidermal Growth Factor; D000069347:Erlotinib Hydrochloride